Abiomed Touts New Study Results, Potential To Revolutionize Heart-Attack Treatment
Promising new results from a pilot study of Abiomed’s Impella device to reduce damage after myocardial infarction sets the company up to start a pivotal study, which, if successful, could change how patients are treated immediately after an attack.
You may also be interested in...
Reported sales and earnings from the publicly traded cardiovascular device companies show strong performance across the sector, spurred by new approvals and clinical trials, in the quarter that ended Sept. 30. Here's a recap of results from the cardio device companies that have reported so far, including Abbott, Abiomed, and Reva.
The lawsuit against Kendall Patient Recovery accuses the company of intentionally ignoring decades of data warning against risks posed by ethylene oxide, causing harm to communities around its facility.
Experts representing manufacturers, patients, providers and federal agencies are being sought by the US government to advise the Office of National Coordinator for Health Information Technology on issues such as health IT standards and specifications.